login
  Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

The impact of the STOP-VT study


Monday, 24 Oct 2011 16:43
Rainer Moosdorf
Rainer Moosdorf


The STOP VT study, as reported in the 14th issue of Cardiac Rhythm News, showed that remote magnetic navigation may provide additional benefits to catheter ablation for the treatment of scar-related ventricular tachycardia. Rainer Moosdorf, Department of Cardiovascular Surgery, Philipps – University Marburg Medical School, Germany, reviews the impact of this study.


 

By Rainer Moosdorf 



The STOP VT study is remarkable in two aspects. The first one is that, with the new magnetic steering technology, ablation of scar related ventricular tachycardia has become more reliable and more successful and the investigators of the study have to be congratulated for their good results. These results should—and this is the second aspect—remind us, that ventricular tachycardia do nearly always have a pathological substrate at the border between scar and vital myocardium, which may be addressed by different ablation techniques as a curative therapy in contrast to the implantable cardioverter device (ICD), which is highly effective in terminating ventricular arrhythmias but is not treating the disease.

 

There are numerous patients with VTs who will benefit from curative attempts not only in terms of cardiac mortality but also in terms of quality of life. This makes a significant difference to the ICD. The new ablation technologies described will widen the field of interventional options and surgical options, and should be considered in any patients with documented VTs and an indication for cardiac surgery.

 

A working group at University Marburg Medical School, including myself, and Robert Svenson, cardiologist and electrophysiologists, Carolinas Heart Center in Charlotte, North Carolina, before retiring, have developed a mapping guided laser ablation technique, which may be applied endo- and epicardially without significantly increasing the procedural time or increasing  the risk of complications during cardiac operations. Importantly we have learned from clinical studies that besides the well known subendocardial re-entry circuits, there are also subepicardial circuits that should be mapped and ablated to avoid recurrences. This is still a weak point of all catheter based techniques, which are limited to a sole endocardial ablation.

 

The endo- and epicardial approach is applied in the presence of major scar or aneurysms and has a cure rate of more than 90% (freedom from any inducible VT) (Moosdorf R, et al. American Heart Journal 1994; 127: 1133–38) and even the sole epicardial ablation, which may avoid a ventriculostomy in the absence of major scar, has a cure rate of around 60% (D Pfeiffer, et al. Circulation 1996; 94:3221–25). This means that with the combined approach, the vast majority of patients may be left without an ICD and will not experience any shocks.

 

Even the limited epicardial ablation provides a success rate of more than half. Additionally, many of the remaining patients, who received an ICD, did not experience a clinical ventricular tachycardia with the necessity of a shock. It may be expected that curative techniques, may they be interventional or surgical, will attract more interest again in the treatment of patients with ventricular tachycardia.

 

 

 

 




Add New Comment

Related Items


Most popular


Abbott to acquire Topera and Advanced Cardiac Therapeutics
Wednesday, 29 Oct 2014
Abbott enters the catheter-based electrophysiology market with the announcement of an agreement to purchase Topera and the securement of the rights to purchase Advanced Cardiac Therapeutics (ACT). B... Abbott to acquire Topera and Advanced Cardiac Therapeutics

Long-term overtreatment with antiplatelet/anticoagulant therapy may increase the risk of dementia in AF patients
Friday, 21 Nov 2014
Atrial fibrillation patients who are receiving a combination of antiplatelet and anticoagulant therapy and are over treated with warfarin may be at an increased risk of dementia, according to a ... Long-term overtreatment with antiplatelet/anticoagulant therapy may increase the risk of dementia in AF patients

FDA approves Cardinal Health MynxGrip Vascular Closure Device for venous indication
Saturday, 08 Nov 2014
Cardinal Health has announced that its MynxGrip Vascular Closure Device recently received Food and Drug Administration (FDA) approval for use to close femoral veins. The MynxGrip device is now ... FDA approves Cardinal Health MynxGrip Vascular Closure Device for venous indication

Features


The challenge of left ventricular lead placement: What is the role of quadripolar leads?
Tuesday, 16 Dec 2014
George H Crossley (Nashville, USA) writes on the role of quadripolar leads in cardiac resynchronisation therapy to treat heart failure patients. The challenge of left ventricular lead placement: What is the role of quadripolar leads?

Highlights from ISCAT 2014
Thursday, 20 Nov 2014
Michel Haïssaguerre and Etienne M Aliot, chairmen of the International Symposium on Catheter Ablation Techniques (ISCAT; 15–17 October 2014, Paris, France), discuss the highlights of this year’s ... Highlights from ISCAT 2014

Profiles


Massimo Santini
Friday, 10 Oct 2014
Massimo Santini performed the first fulguration of the atrioventricular node of resistant ... Massimo Santini

Nick Linker
Monday, 14 Jul 2014
Nick Linker is president-elect of the British Heart Rhythm Society (BHRS) and programme director of ... Nick Linker

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions